lenalidomide accord 7,5 mg
pharmadox healthcare limited - malta - lenalidomidum - caps. - 7,5mg - imunosupresoare alte imunosupresoare
lenalidomide krka 10 mg
krka d.d. novo mesto - slovenia - lenalidomidum - caps. - 10mg - imunosupresoare alte imunosupresoare
lenalidomide krka 15 mg
krka d.d. novo mesto - slovenia - lenalidomidum - caps. - 15mg - imunosupresoare alte imunosupresoare
lenalidomide krka 2,5 mg
krka d.d. novo mesto - slovenia - lenalidomidum - caps. - 2,5mg - imunosupresoare alte imunosupresoare
lenalidomide krka 20 mg
krka d.d. novo mesto - slovenia - lenalidomidum - caps. - 20mg - imunosupresoare alte imunosupresoare
lenalidomide krka 25 mg
krka d.d. novo mesto - slovenia - lenalidomidum - caps. - 25mg - imunosupresoare alte imunosupresoare
lenalidomide krka 5 mg
krka d.d. novo mesto - slovenia - lenalidomidum - caps. - 5mg - imunosupresoare alte imunosupresoare
lenalidomide krka 7,5 mg
krka d.d. novo mesto - slovenia - lenalidomidum - caps. - 7,5mg - imunosupresoare alte imunosupresoare
sarclisa
sanofi winthrop industrie - isatuximab - mielom multiplu - agenți antineoplazici - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.
lenalidomida sandoz 10 mg
synthon hispania, s.l. - spania - lenalidomidum - caps. - 10mg - imunosupresoare alte imunosupresoare